CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has ...
Hosted on MSN1d
Chardan Capital Downgrades CervoMed (CRVO)
Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
Finanznachrichten10h
CervoMed Inc.: CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...
FierceBiotech2d
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...
CervoMed: Neflamapimod Phase 2b Trial In Dementia With Lewy Bodies Patients Fails To Meet Targets
CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...
Morgan Stanley downgrades CervoMed (CRVO) to a Sell
CervoMed (CRVO – Research Report) received a Sell rating and price target from Morgan Stanley analyst Jeffrey Hung today. The company’s ...
bovnews20h
CervoMed Inc (CRVO) Posted -118.68% Profit Margin Last Year—Can It Hold Up?
On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...
CervoMed Shares Slide to All-Time Low After Study Failure
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...